NCT04041882 is a EARLY_PHASE1 clinical trial of 68Ga-DOTATATE in Neuroendocrine Tumors, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT04041882?

NCT04041882 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04041882?

Interventions in NCT04041882: 68Ga-DOTATATE.

What condition does NCT04041882 study?

NCT04041882 studies Neuroendocrine Tumors.

Is NCT04041882 still recruiting?

NCT04041882 is currently status unknown. Last updated 1 August 2019.

Last reviewed 2019-08-01 · How we verify

NCT04041882

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

68Ga-DOTATATE PET/CT in Neuroendocrine Tumor

Status unknown EARLY_PHASE1 Last updated 1 August 2019

What this trial tests

EARLY_PHASE1 trial testing 68Ga-DOTATATE in Neuroendocrine Tumors in 100 participants. Status unknown.

Timeline

1 April 2014

Primary endpoint
30 December 2020

30 January 2022

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	1 April 2014
Primary completion	30 December 2020
Estimated completion	30 January 2022
Sites	1 location across China

Drugs / interventions tested

68Ga-DOTATATE

Conditions studied

Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 7 to 80, any sex, with Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Somatostatin receptor(SSTR) was expressed in neuroendocrine tumor cells and SSTR-targeting molecular imaging(68Ga-DOTATATE PET/CT) could be a promising technique to evaluate the primary tumor and metastatic lesions of neuroendocrine tumors with higher accuracy. This prospective study is going to investigate whether radiolabeled somatostatin analogs 68Ga-DOTATATE PET/CT may be valuable for diagnosis, risk stratification, and prognostic evaluation of neuroendocrine tumors and compared it with 18F-FDG PET/CT.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Tracers and Radionuclides in PET Imaging.
Mason C, Gimblet GR, Lapi SE, Lewis JS. · · 2021 · cited 10× · PMID 34392925 · DOI 10.1016/j.rcl.2021.05.012
Head-to-head comparison of <sup>68</sup>Ga-DOTATATE PET/CT and <sup>18</sup>F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study.
Liu Q, Zang J, Yang Y, Ling Q, et al · · 2021 · cited 9× · PMID 34146130 · DOI 10.1007/s00259-021-05370-8

Verify or expand the search:

Other trials of 68Ga-DOTATATE

Trials testing the same drug.

NCT06479811 — [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, · Phase 1 · recruiting
NCT06427798 — Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendoc · Phase 1, PHASE2 · recruiting
NCT06056362 — Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroend · Phase 1, PHASE2 · recruiting
NCT04069299 — Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract · completed
NCT02019706 — Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome · Phase 2 · recruiting

Other recruiting trials for Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04041882 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 1 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04041882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing